Genmab (ADR)
Develops antibody medicines through partner royalties, co-commercialization, and a wholly owned oncology portfolio.
Something off on this page? Send us feedback.
Profile
Develops antibody medicines and platforms, earning royalties from partner-marketed products while co-commercializing EPKINLY/TEPKINLY and independently selling Tivdak in Europe and Japan. A Copenhagen-based global organization is building wholly owned oncology programs, while revenue and pipeline progress depend on partners and clinical, regulatory, manufacturing, and launch execution.
Develops antibody medicines from Copenhagen using proprietary bispecific, hexamerization, and antibody-drug conjugate technologies. Revenue combines royalties from partner-marketed medicines with product sales, milestones, collaboration payments, and license fees.
Partner products include DARZALEX, Kesimpta, RYBREVANT, TECVAYLI, TALVEY, and TEPEZZA. EPKINLY/TEPKINLY is co-commercialized with AbbVie, while Tivdak's European and Japanese launches established an independent commercial channel across a business spanning North America, Europe, and Asia-Pacific.
Wholly owned oncology programs include Rina-S and petosemtamab, supported by technologies and teams added through ProfoundBio and Merus. The operating model relies on partners' sales and development execution for royalties, and on clinical, regulatory, manufacturing, launch, acquisition-integration, and financing execution for proprietary medicines.
Company facts
Key statistics
Year to date +4.4% · Average volume (30d) 2.5M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 22, 2026 | Cowen & Co. | Upgrade | Hold | Buy | ||
| Jul 22, 2026 | New Street | Target | $43 | |||
| Jul 22, 2026 | TD Cowen | Upgrade | Hold | Buy | ||
| May 27, 2026 | Truist Financial | Target | $48 | $40 | ||
| Apr 30, 2026 | H.C. Wainwright | Target | $39 | $38 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | $0.37 | $0.54 | +45.9% | $1.12B | $1.16B | +3.5% | +1.95% |
| May 7, 2026Q1 FY26 | $0.15 | $0.15 | 0.0% | $905.8M | $896.0M | −1.1% | −2.33% |
| Feb 17, 2026Q4 FY25 | $0.46 | $0.05 | −89.1% | $1.07B | $1.06B | −0.8% | −2.80% |
| Nov 6, 2025Q3 FY25 | $0.48 | $0.65 | +35.4% | $1.01B | $1.02B | +1.1% | −0.62% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $105.2M | $924.8M | $1.02B | $1.05B | $899.3M | $1.16B | |
| Gross profit | $99.1M | $867.8M | $964.0M | $974.1M | $834.1M | $1.07B | |
| Operating income | $27.7M | $359.9M | $459.0M | $242.3M | $225.8M | $407.0M | |
| Net income | $28.7M | $335.9M | $401.0M | $30.9M | $53.2M | $303.0M | |
| Diluted EPS | $0.05 | $0.54 | $0.65 | $0.05 | $0.08 | $0.49 | |
| Gross margin | 94.1% | 93.8% | 94.3% | 92.3% | 92.7% | 92.7% | |
| Operating margin | 26.3% | 38.9% | 44.9% | 23.0% | 25.1% | 35.2% |
Fiscal years (4-quarter sums)FY21 $8.48B · FY22 $14.51B · FY23 $16.39B · FY24 $13.36B · FY25 $3.11B
Balance sheet, Jun 30, 2026Cash & short-term investments $1.50B · Total debt $5.27B · Total assets $12.52B · Shareholders' equity $5.96B
Dividends
No dividends on record.
Ownership
Shares outstanding 613.94M · Float 606.43M · 98.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 13.13M | 2.14% | 13F | Aug 14, 2026 |
| Orbis Allan Gray Ltd | 11.37M | 1.85% | 13F | Aug 14, 2026 |
| AllianceBernstein L.P. | 8.64M | 1.41% | 13F | Aug 14, 2026 |
| Deerfield Management Company, L.P. (Series C) | 6.87M | 1.12% | 13F | Aug 14, 2026 |
| Deep Track Capital, LP | 5.65M | 0.92% | 13F | Aug 14, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- AbbVie
FRα-targeted ADC rival in gynecologic oncology
- Regeneron
CD20×CD3 bispecific rival in relapsed/refractory lymphoma
- Eli Lilly
Dual rival in FRα ADCs and EGFR-targeted head-and-neck cancer
- Bristol-Myers Squibb
Cell-therapy and checkpoint rival across lymphoma and cervical cancer
- Merck
Checkpoint-inhibitor rival in cervical and head-and-neck cancer
- AstraZeneca (ADR)
Late-stage FRα ADC rival in gynecologic oncology
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Genmab (ADR) | $33.25 | +0.09% | $20.40B | 26.2 | 25.9 | 2.1 | +24.9% |
| AbbVie | $255.80 | +0.13% | $451.38B | 72.0 | 16.8 | 7.0 | +10.2% |
| Regeneron | $793.21 | −0.11% | $81.82B | 19.6 | 13.1 | 5.3 | +16.7% |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| Merck | $148.19 | −0.08% | $366.18B | 118.7 | 17.2 | 5.5 | +5.1% |
| AstraZeneca (ADR) | $161.79 | −0.55% | $252.33B | 24.4 | 15.2 | 4.1 | +6.4% |
| Median | 31.9 | 16.0 | 5.4 | +8.3% |